1. Choi H, Lee HK, Park HM. The Korean menopausal women`s attitudes and awareness on menopause: results of Korean gallup epidemiologic survey on menopause and HRT. J Korean Soc Menopause. 2003; 9:36–43.
2. Deeks A, Zoungas S, Teede H. Risk perception in women: a focus on menopause. Menopause. 2008; 15:304–309.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.
4. Chung YJ, Kim MR, Jeong HW, Yoon BK, Lee BS, Kang BM, et al. Changing Korean Menopausal Women's Awareness on Hormone Therapy: 7-years after Women's Health Initiative Study. J Korean Soc Menopause. 2012; 18:94–99.
5. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010; 17:242–255.
6. Newton KM, Reed SD, Grothaus LC, La Croix AZ, Nekhlyudov L, Ehrlich K, et al. Hormone therapy discontinuation: physician practices after the Women's Health Initiative. Menopause. 2010; 17:734–740.
7. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril. 2005; 83:558–566.
8. Sturdee DW, Pines A, Archer DF, Baber RJ, Barlow D, Birkhauser MH, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14:302–320.
9. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291:47–53.